What significant monitoring is required when a patient is on Dofetilide?

When a patient is on Dofetilide, it is crucial to perform lengthy ECG monitoring for QTc changes due to the drug's potential to prolong the QT interval, which can lead to life-threatening arrhythmias such as Torsades de Pointes. Dofetilide is a class III antiarrhythmic medication primarily used for treating atrial fibrillation and atrial flutter, and it works by blocking potassium channels, which affects cardiac repolarization.

Monitoring the QTc interval closely allows healthcare providers to assess the risk of arrhythmias, adjust the dosage appropriately, and implement necessary interventions if significant changes occur. This monitoring is especially critical during the first few days of treatment, as the risk of QT prolongation is greatest during this time, particularly in patients with renal impairment, electrolyte imbalances, or those on other medications that can also prolong the QT interval.

The other options, while they may be important in certain contexts, do not address the primary concern associated with Dofetilide therapy. For instance, daily blood pressure monitoring is less critical than ECG due to the medication's specific cardiac effects. Regular complete blood counts are not routinely required for patients on Dofetilide, nor are liver function